Skip to main content

""

Ongoing Private
Sector Projects

The following projects are currently being completed by DAS. Projects are listed in the order in which Research Ethics Board approval was obtained.

Client: IQVIA Solutions Canada Inc.

Project ID: P2018-040/2020 0970 173 000

Research Question/Objectives: In December 2015, mepolizumab, was approved in Canada as add-on maintenance for the treatment of adult patients with uncontrolled eosinophilic severe asthma. Despite compelling clinical trial evidence, many stakeholders still seek to better understand if the value seen in randomized studies is realized in actual clinical practice. Now, with over two years of real-world data available, this study would like to investigate the real-world impact of mepolizumab on asthma related clinical outcomes, healthcare resource use and costs among severe asthma patients, outside of the randomized clinical trial setting. The objective of the current research project primarily is to estimate the demographic and cliccal characteristics of real-world mepolizumab patients. The project team is also interested in comparison of asthma related real-world outcomes of post-mepolizumab initiation versus pre-mepolizumab initiation.

Research objectives

Primary Objectives:

  • Describe the demographic and clinical characteristics of real-world mepolizumab patients to understand the population with mepolizumab utilization.
  • Compare asthma-related real-world outcomes (listed below) for mepolizumab patients (post-mepolizumab initiation) versus pre-mepolizumab initiation among the same patients to determine the effectiveness of mepolizumab in actual clinical practice.
  • Compare costs associated with asthma-related real-world outcomes for mepolizumab patients (post-mepolizumab initiation) versus pre-mepolizumab initiation among same patients to evaluate the differences from the public payer’s perspective.

Secondary Objective:

  • Investigate the real-world asthma-related outcomes and associated costs (as listed above under primary objectives) for highly adherent (≥ 9 injections) mepolizumab patients (i.e. sub cohort) post versus premepolizumab initiation to understand the impact of mepolizumab among patients who are highly adherent.

Availability of Results: study in progress


Client: Sunnybrook Research Institute/HOPE Research Centre

Project ID: P2020-078/2022 0970 259 000

Research Question/Objectives: The client is looking for Canadian specific costs of various resources associated with three types of cancers for a model that requires cost, outcomes, and patient inputs.

Cost, outcomes, and patient inputs and utilization rates of various resources will be identified for the following cohorts of cancers:

  • Breast cancer
  • Biliary tract cancer
  • Hepatocellular carcinoma.

Availability of Results: study in progress

Client: IQVIA Solutions Canada Inc.

Project ID: P2020-083/2022 0970 264 000

Research Question/Objectives: Glaucoma is a family of diseases characterized by the loss of retinal ganglion cells and their nerve fibers leading to progressive, irreversible loss of visual function. It is the second leading cause of severe visual impairment and blindness worldwide Primary open-angle glaucoma is the most common form of glaucoma and was estimated to affect 44.11 million people aged 40-80 years worldwide in 2013. The study aims to describe real-world patient characteristics, treatment patterns, and outcomes in patients newly diagnosed with OAG in Canada, overall and by patient subgroups.

The specific aims are to:

  • Describe baseline patient demographic and clinical characteristics, including comorbidities (ocular and non-ocular).
  • Evaluate treatment patterns of topical glaucoma medications and rate of glaucoma-related surgeries/procedures.
  • Estimate direct healthcare resource utilization (HCRU).

Availability of Results: In progress


Client: Charles River Associates

Project ID: P2020-077 / 2022 0970 271 000

Research Question/Objectives: Pulmonary arterial hypertension (PAH) is a rare disease with a limited understanding of the current epidemiology in Canada. PAH is associated with an elevated mortality risk, especially if left untreated. Our client has a product in development for the treatment of PAH with an expected commercial launch in the Canadian market in the near future. By improving the understanding of the treated natural history, PAH can be treated earlier and more efficiently, improving the overall survival rate of affected patients in Ontario.

The specific research objectives are:

  • What is the estimated prevalence of PAH in Ontario?
  • What is the patient profile of patients with PAH?
  • How are patients currently being treated for PAH?
  • Which specialty types are treating PAH patients and in what setting?
  • What is the health resource utilization for PAH patients?

Availability of Results: In progress


Client: IQVIA Solutions Canada Inc.

Project ID: P2020-089 / 2022 0970 291 000

Research Question/Objectives: Respiratory syncytial virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms, but can have serious consequences, especially among infants and older adults. In Canada, RSV is responsible for 1042 hospitalizations per 100,000 infants per year and over 100 hospitalizations per 100 000 of those over the age of 75 years, with mortality as high as 41% among those with underlying medical conditions. The present study aims to evaluate the direct health care resource utilization (HCRU) and associated costs incurred by the public payer for RSV patients in Ontario.

Research objectives:

  • Describe the count of patients hospitalized for RSV in Ontario.
  • Describe the demographic characteristics and HCRU of patients hospitalized for RSV in Ontario, overall and with specific outcomes.
  • Describe the direct healthcare costs of patients hospitalized for RSV in Ontario, overall and with specific outcomes, matched to controls.

Availability of Results: In progress


Client: IQVIA Solutions Canada Inc.

Project ID: P2020-090 / 2021 0970 285 000

Research Question/Objectives: The purpose of this study is to describe the patient pathways for obesity management at hospital and/or specialized obesity services in Canada. Treatment patterns defined by the initiation, discontinuation, sequence, timing and duration of specific obesity interventions, as well as the concurrent healthcare resource utilization (HCRU) will be described for patients with body mass index (BMI) ≥30 kg/m2.

Research objectives:

  • Describe the real-world obesity care pathway for patients BMI ≥30 kg/m2, from their first obesity clinic visit to the end of follow up, by summarizing patients’ interactions with the healthcare system in Canada.
  • Describe key patient characteristics (e.g., BMI, age, presence of comorbidities, Charlson Comorbidity Index) at specialist entry of the obesity care pathway.
  • Describe what professionals (e.g., endocrinologists, surgeons, etc.) are involved in obesity management throughout the obesity care pathway.
  • Describe the frequency, timing and duration of obesity treatment received along the obesity care pathway, including initiation, stopping and retreatment patterns, for the following types of obesity interventions: lifestyle modifications, pharmacological interventions, bariatric endoscopy, bariatric surgery.
  • Describe HCRU throughout the obesity care pathway.
  • Describe the incidence of key obesity-related comorbidities along the obesity care pathway (including, but not limited to, pre diabetes, type 2 diabetes [T2D], cardiovascular disease [CVD], others).
  • If feasible, to evaluate the increase in HCRU and direct cost (assessed during follow-up) attributable to comorbidities, adjusting for relevant demographic and clinical characteristics (including BMI and changes in BMI over the follow-up period).
  • Subject to adequate sample size, study objectives (when applicable) will be evaluated separately for patients in obesity class I (BMI 30-35), class II (BMI 35-40) and class III (BMI 40-45) at entry of the pathway, patients with and without comorbidities of interest (independently for each comorbidity) and patients who did or did not undergo bariatric surgery/endoscopy during follow-up.

Availability of Results: In progress


Client: IQVIA Solutions Canada Inc.

Project ID: P2022-107/ 2023 0970 305 000

Research Question/Objectives: Renal Cell Carcinoma (RCC) is the most common type of kidney cancer, and accounts for approximately 2% of new cancers. As the disease progresses, RCC can be treated with nephrectomy and drug therapies such as immunotherapy and targeted therapy. Despite its relatively high burden, the population burden of RCC is not well described in the published literature, especially as the disease progresses. The proposed study looks to quantify the disease burden of RCC along the RCC patient journey using administrative data health at ICES.

Research objectives:

  • Identify RCC patients and their distribution by disease progression within the health administrative data held at ICES.
  • Describe the characteristics of these cancer patients in Ontario, including: incidence (i.e., new patients); prevalence (i.e. existing patients); and demographic and clinical characteristics.

Availability of Results: Study in progress




×